Four-Point Preprandial Self-Monitoring of Blood Glucose for the Assessment of Glycemic Control and Variability in Patients with Type 2 Diabetes Treated with Insulin and Vildagliptin
The study explored the utility of four-point preprandial glucose self-monitoring to calculate several indices of glycemic control and variability in a study adding the DPP-4 inhibitor vildagliptin to ongoing insulin therapy. This analysis utilized data from a double-blind, randomized, placebo-contro...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2015-01-01
|
| Series: | International Journal of Endocrinology |
| Online Access: | http://dx.doi.org/10.1155/2015/484231 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850209960429879296 |
|---|---|
| author | Andrea Tura Johan Farngren Anja Schweizer James E. Foley Giovanni Pacini Bo Ahrén |
| author_facet | Andrea Tura Johan Farngren Anja Schweizer James E. Foley Giovanni Pacini Bo Ahrén |
| author_sort | Andrea Tura |
| collection | DOAJ |
| description | The study explored the utility of four-point preprandial glucose self-monitoring to calculate several indices of glycemic control and variability in a study adding the DPP-4 inhibitor vildagliptin to ongoing insulin therapy. This analysis utilized data from a double-blind, randomized, placebo-controlled crossover study in 29 patients with type 2 diabetes treated with vildagliptin or placebo on top of stable insulin dose. During two 4-week treatment periods, self-monitoring of plasma glucose was undertaken at 4 occasions every day. Glucose values were used to assess several indices of glycemic control quality, such as glucose mean, GRADE, M-VALUE, hypoglycemia and hyperglycemia index, and indices of glycemic variability, such as standard deviation, CONGA, J-INDEX, and MAGE. We found that vildagliptin improved the glycemic condition compared to placebo: mean glycemic levels, and both GRADE and M-VALUE, were reduced by vildagliptin (P<0.01). Indices also showed that vildagliptin reduced glycemia without increasing the risk for hypoglycemia. Almost all indices of glycemic variability showed an improvement of the glycemic condition with vildagliptin (P<0.02), though more marked differences were shown by the more complex indices. In conclusion, the study shows that four-sample preprandial glucose self-monitoring is sufficient to yield information on the vildagliptin effects on glycemic control and variability. |
| format | Article |
| id | doaj-art-9786fdb99d2744b2bc62231ed106a332 |
| institution | OA Journals |
| issn | 1687-8337 1687-8345 |
| language | English |
| publishDate | 2015-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Endocrinology |
| spelling | doaj-art-9786fdb99d2744b2bc62231ed106a3322025-08-20T02:09:52ZengWileyInternational Journal of Endocrinology1687-83371687-83452015-01-01201510.1155/2015/484231484231Four-Point Preprandial Self-Monitoring of Blood Glucose for the Assessment of Glycemic Control and Variability in Patients with Type 2 Diabetes Treated with Insulin and VildagliptinAndrea Tura0Johan Farngren1Anja Schweizer2James E. Foley3Giovanni Pacini4Bo Ahrén5CNR Institute of Neuroscience, Corso Stati Uniti 4, 35127 Padova, ItalyDepartment of Clinical Sciences, Lund University, B11 BMC, 22184 Lund, SwedenNovartis Pharma AG, 4002 Basel, SwitzerlandNovartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, NJ 07936, USACNR Institute of Neuroscience, Corso Stati Uniti 4, 35127 Padova, ItalyDepartment of Clinical Sciences, Lund University, B11 BMC, 22184 Lund, SwedenThe study explored the utility of four-point preprandial glucose self-monitoring to calculate several indices of glycemic control and variability in a study adding the DPP-4 inhibitor vildagliptin to ongoing insulin therapy. This analysis utilized data from a double-blind, randomized, placebo-controlled crossover study in 29 patients with type 2 diabetes treated with vildagliptin or placebo on top of stable insulin dose. During two 4-week treatment periods, self-monitoring of plasma glucose was undertaken at 4 occasions every day. Glucose values were used to assess several indices of glycemic control quality, such as glucose mean, GRADE, M-VALUE, hypoglycemia and hyperglycemia index, and indices of glycemic variability, such as standard deviation, CONGA, J-INDEX, and MAGE. We found that vildagliptin improved the glycemic condition compared to placebo: mean glycemic levels, and both GRADE and M-VALUE, were reduced by vildagliptin (P<0.01). Indices also showed that vildagliptin reduced glycemia without increasing the risk for hypoglycemia. Almost all indices of glycemic variability showed an improvement of the glycemic condition with vildagliptin (P<0.02), though more marked differences were shown by the more complex indices. In conclusion, the study shows that four-sample preprandial glucose self-monitoring is sufficient to yield information on the vildagliptin effects on glycemic control and variability.http://dx.doi.org/10.1155/2015/484231 |
| spellingShingle | Andrea Tura Johan Farngren Anja Schweizer James E. Foley Giovanni Pacini Bo Ahrén Four-Point Preprandial Self-Monitoring of Blood Glucose for the Assessment of Glycemic Control and Variability in Patients with Type 2 Diabetes Treated with Insulin and Vildagliptin International Journal of Endocrinology |
| title | Four-Point Preprandial Self-Monitoring of Blood Glucose for the Assessment of Glycemic Control and Variability in Patients with Type 2 Diabetes Treated with Insulin and Vildagliptin |
| title_full | Four-Point Preprandial Self-Monitoring of Blood Glucose for the Assessment of Glycemic Control and Variability in Patients with Type 2 Diabetes Treated with Insulin and Vildagliptin |
| title_fullStr | Four-Point Preprandial Self-Monitoring of Blood Glucose for the Assessment of Glycemic Control and Variability in Patients with Type 2 Diabetes Treated with Insulin and Vildagliptin |
| title_full_unstemmed | Four-Point Preprandial Self-Monitoring of Blood Glucose for the Assessment of Glycemic Control and Variability in Patients with Type 2 Diabetes Treated with Insulin and Vildagliptin |
| title_short | Four-Point Preprandial Self-Monitoring of Blood Glucose for the Assessment of Glycemic Control and Variability in Patients with Type 2 Diabetes Treated with Insulin and Vildagliptin |
| title_sort | four point preprandial self monitoring of blood glucose for the assessment of glycemic control and variability in patients with type 2 diabetes treated with insulin and vildagliptin |
| url | http://dx.doi.org/10.1155/2015/484231 |
| work_keys_str_mv | AT andreatura fourpointpreprandialselfmonitoringofbloodglucosefortheassessmentofglycemiccontrolandvariabilityinpatientswithtype2diabetestreatedwithinsulinandvildagliptin AT johanfarngren fourpointpreprandialselfmonitoringofbloodglucosefortheassessmentofglycemiccontrolandvariabilityinpatientswithtype2diabetestreatedwithinsulinandvildagliptin AT anjaschweizer fourpointpreprandialselfmonitoringofbloodglucosefortheassessmentofglycemiccontrolandvariabilityinpatientswithtype2diabetestreatedwithinsulinandvildagliptin AT jamesefoley fourpointpreprandialselfmonitoringofbloodglucosefortheassessmentofglycemiccontrolandvariabilityinpatientswithtype2diabetestreatedwithinsulinandvildagliptin AT giovannipacini fourpointpreprandialselfmonitoringofbloodglucosefortheassessmentofglycemiccontrolandvariabilityinpatientswithtype2diabetestreatedwithinsulinandvildagliptin AT boahren fourpointpreprandialselfmonitoringofbloodglucosefortheassessmentofglycemiccontrolandvariabilityinpatientswithtype2diabetestreatedwithinsulinandvildagliptin |